

University of Groningen

Pharmacokinetics and optimal exposure of antifungal drugs in critically ill patients

van der Elst, Kimberly Corina Maria

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2015

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

van der Elst, K. C. M. (2015). *Pharmacokinetics and optimal exposure of antifungal drugs in critically ill patients*. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

List of publications

1. **K.C.M. van der Elst**, C.H.S. Brouwers, E.R. van den Heuvel *et al.*, "Subtherapeutic posaconazole exposure and the relation with treatment outcome in patients at risk of and with invasive fungal disease.", *Ther. Drug. Mon., under review*.
2. **K.C.M. van der Elst**, M. van Alst, M.N. Lub-de Hooge *et al.*, "Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children.", *Antimicrob. Agents Chemother.* **58**, 11 (2014), 6742-6.
3. **K.C.M. van der Elst**, M. Pereboom, E.R. van den Heuvel *et al.*, "Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children.", *Clin. Infect. Dis.* **59**, 11 (2014), 1527-33.
4. **K.C.M. van der Elst**, L.F.R. Span, K. van Hateren *et al.*, "Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole.", *Antimicrob. Agents Chemother.* **57**, 10 (2013), 4999-5004.
5. M.J.P. van Wanrooy, R.N. Santoe, **K.C.M. van der Elst** *et al.*, "Simultaneous quantification of anidulafungin and caspofungin in plasma by an accurate and simple liquid chromatography tandem mass-spectrometric method.", *Ther. Drug Monit.* **35**, 6 (2013), 778-84.
6. D.R.A. Uges & **K.C.M. van der Elst**, "Farmacotherapie en klinische toxicologie, een twee-eenheid.", *MFM Tijdschrift over praktijkgerichte farmacotherapie* **4** (2013), 42-45.
7. **K.C.M. van der Elst**, R.J.M. Brüggemann, M.G.G. Rodgers *et al.*, "Plasma concentrations of caspofungin at two different dosage regimens in a patient with

- hepatic dysfunction.", *Transpl. Infect. Dis.* **14**, 4, (2012), 440-3.
8. **K.C.M. van der Elst**, D.R.A. Uges, J.W.C. Alffenaar, "Validation parameters cannot be obtained without using pure substance.", *J. Pharm. Biomed. Anal.* **56**, 2 (2011), 462-3.
 9. **K.C.M. van der Elst**, S.G. Schorr, M.J. Postma *et al.*, "Screening op diabetes bij patinten met een psychotische stoornis is kosteneffectief.", *PW Wetenschappelijk Platform* **5**, 3 (2011), 44-48.
 10. J.W.C. Alffenaar, **K.C.M. van der Elst**, D.R.A. Uges *et al.*, "Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage.", *Br. J. Clin. Pharmacol.* **68**, 3 (2009), 462-3.
 11. R. Bruggeman, S.G. Schorr, **K.C.M. van der Elst et al.**, "Cost-effectiveness of screening for diabetes in a cohort of patients with schizofrenia.", *Schizophrenia Research* **102**, 1 (2008), 161-162.
 12. D.R.A. Uges & **K.C.M. van der Elst**, "Hoofdstuk: Toxicologie en bloedspiegelbepalingen", *Farmacotherapeutisch Kompas*.